Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.1%

33 terminated/withdrawn out of 149 trials

Success Rate

54.8%

-31.7% vs industry average

Late-Stage Pipeline

11%

17 trials in Phase 3/4

Results Transparency

113%

45 of 40 completed trials have results

Key Signals

40 recruiting45 with results30 terminated

Enrollment Performance

Analytics

Phase 1

66(44.9%)

Phase 2

63(42.9%)

Phase 3

16(10.9%)

Phase 4

1(0.7%)

N/A

1(0.7%)

147Total

Phase 1(66)

Phase 2(63)

Phase 3(16)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (149)

Showing 20 of 149 trials

NCT04022343Phase 2Active Not Recruiting

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Role: collaborator

NCT07226063Phase 2Not Yet Recruiting

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Role: collaborator

NCT07227402Phase 3Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Role: collaborator

NCT07489495Phase 3Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Role: collaborator

NCT06835972Phase 1Recruiting

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Role: collaborator

NCT04631744Phase 2Terminated

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Role: collaborator

NCT07043608Phase 2Not Yet Recruiting

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Role: collaborator

NCT04472767Phase 2Recruiting

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Role: collaborator

NCT04878029Phase 1Recruiting

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Role: collaborator

NCT06959511Phase 2Recruiting

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Role: collaborator

NCT06943755Phase 2Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Role: lead

NCT07283731Phase 2Recruiting

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Role: collaborator

NCT06545331Phase 1Recruiting

Study of XB010 in Subjects With Solid Tumors

Role: lead

NCT05249114Phase 1Active Not Recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Role: collaborator

NCT05048212Phase 2Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Role: collaborator

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT04963283Phase 2Active Not Recruiting

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Role: collaborator

NCT07049926Phase 1Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Role: collaborator

NCT07484139Phase 2Not Yet Recruiting

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Role: collaborator

NCT04338269Phase 3Terminated

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Role: collaborator